Showing 4001-4010 of 8659 results for "".
- Delgocitinib Clinical Trials Data Publishedhttps://practicaldermatology.com/news/delgocitinib-clinical-trials-data-published/2467444/LEO Pharma A/S announced that the findings of the DELTA 1 and DELTA 2 phase 3 clinical trials for delgocitinib cream have been published in the peer-reviewed periodical The Lancet. This is the first time The Lancet has published data on an investigational topical pan-Janus kinase (JAK) inhibitor
- Analysis: Ruxolitinib 1.5% Cream Linked with Repigmentation in Adolescents with Vitiligohttps://practicaldermatology.com/news/phase-3-trials-reveal-enhanced-repigmentation-adolescents-vitiligo/2467443/A new post-hoc analysis indicates significant repigmentation results from the application of 1.5% ruxolitinib cream in patients with nonsegmental vitiligo. The analysis looked at two double-blind, vehicle-controlled studies (the TRuE-V1 and TRuE-V2 phase 3 clinical trials). Patients were
- Study: CBD Cream Shows Promise in Reducing Sun-Induced Skin Injuryhttps://practicaldermatology.com/news/study-cbd-cream-shows-promise-reducing-sun-induced-skin-injury/2467423/New research from the George Washington University School of Medicine and Health Sciences, in collaboration with the Center for Clinical and Cosmetic Research, suggests that cannabidiol (CBD) has potential in preventing skin damage from ultraviolet-A (UVA) radiation. Researchers for the 1
- Taylor Fritz Partners with La Roche-Posay for Sun Safety Campaignhttps://practicaldermatology.com/news/taylor-fritz-partners-la-roche-posay-sun-safety-campaign/2467419/La Roche-Posay has partnered with professional tennis player Taylor Fritz to promote awareness of sun safety practices, according to a news release. Taylor Fritz, currently the highest-ranked American male tennis player, will serve as the sun safety spokesperson for La Roche-Posay to high
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis
- AQUA Dermatology Partners With First Coast Mohshttps://practicaldermatology.com/news/aqua-dermatology-partners-first-coast-mohs/2467290/AQUA Dermatology, backed by private-equity firms Gryphon Investors and GTCR, announced it now has 110 locations in the southeastern United States and more than 250 practitioners as a result of a new partnership with Jacksonville, Florida-based First Coast Mohs. First Coast Mohs will conti
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://practicaldermatology.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- Promotional vs. Educational: Skin Condition Posts on Instagram and TikTokhttps://practicaldermatology.com/news/promotional-vs-educational-skin-condition-posts-instagram-and-tiktok/2467249/New research revealed differences in the types of dermatology content present on the Instagram and TikTok social media platforms. Researchers publishing in the Journal of Drugs in Dermatology looked specifically at content on the Instagram and TikTok social media platforms relat
- Survey: Just 40% See Dermatologists Annually Despite Skin Concernshttps://practicaldermatology.com/news/survey-just-40-see-dermatologists-annually-despite-skin-concerns/2467226/Manufacturer CeraVe has announced findings from a new survey suggesting that while 80% of participants experienced skin concerns, just 40% of them visited a dermatologist for an annual skin exam. The survey of 1,000 American adults also revealed that 25% suffered from serious skin condit
- Inaugural ElderDerm Conference Hosted by GWhttps://practicaldermatology.com/news/inaugural-elderderm-conference-hosted-gw/2467204/The inaugural ElderDerm Conference was held June 6 in Washington, DC, hosted by the GW Department of Dermatology. Co-Director Adam Friedman, MD, a Practical DermatologyÒ Editorial Board member, presented two talks: “Hair Loss in the Elderly: Considerations and Therapeutic Approaches” and